Primex Pharmaceuticals AG, a Switzerland-based pharmaceutical company, has named Dan Spacie as its new global commercial head, it was reported yesterday.
Dan Spacie joined Primex Pharmaceuticals from Syneos Health, where he was president, Commercial, Europe. Prior to Syneos, he held several leadership roles including managing director at STADA UK affiliates for five years. He has extensive international leadership experience in growing sales and enhancing profitability of generics, branded pharmaceuticals and launching biopharmaceuticals.
In the new role, Spacie is responsible for global Commercialisation, working with both the company's partners and direct field forces across the portfolio and with the launch of OZALIN in the European Union. He will be part of the executive team headed by CEO Alan Knox and is based in Zug, Switzerland.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream